Photo of Shiow-Lin Pan

View Scopus Profile

Shiow-Lin Pan

Professor

 https://orcid.org/0000-0001-7449-3539
  • 2951 Citations
  • 32 h-Index
19962020
If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2002 Ph.D. National Taiwan University
  • 1994 M.S. Taipei Medical University

Experience

  • 2019- Director, Ph.D Program in Biotechnology Research and Development, Taipei Medical University
  • 2018- Professor, Master Program in Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University
  • 2016-2018 Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2013-2016 Associate Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, Taipei Medical University
  • 2008-2013 Assistant Professor, Department of Pharmacology, Taipei Medical University
  • 2009-2013 Assistant Investigator, National Health Research Institutes
  • 2007-2009 Assistant Investigator, National Taiwan University
  • 2002-2007 Postdoctor, National Taiwan Universiy
  • 1994-1998 Teaching Assistant, Chang-Gung University

Research Interests

  • Drug Discovery
  • Disease animal model
  • Pharmacology

URL

Fingerprint Dive into the research topics where Shiow-Lin Pan is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles
Apoptosis Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Histone Deacetylase Inhibitors Medicine & Life Sciences
Cells Chemical Compounds
Smooth Muscle Myocytes Medicine & Life Sciences
Heterografts Medicine & Life Sciences
Growth Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2020

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(2/3)

Pan, S.

8/1/19 → 7/1/20

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究(II)

Pan, S.

5/1/19 → 10/1/19

Project: A - Government Institution › b - Ministry of Science and Technology

新穎性選擇性HDAC抑制劑之抗癌藥物開發與藥理機轉探討(1/3)

Pan, S.

8/1/18 → 7/1/19

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性抗癌標靶藥物HDAC6抑制劑臨床前試驗研究

Pan, S.

12/1/17 → 10/31/18

Project: A - Government Institution › b - Ministry of Science and Technology

選擇性HDAC1及2抑制劑作為新穎性抗癌藥物之藥物開發與藥理機轉探討

Pan, S.

8/1/17 → 7/31/18

Project: A - Government Institution › b - Ministry of Science and Technology

Research Output 1996 2019

  • 2951 Citations
  • 32 h-Index
  • 126 Article

Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells

Nepali, K., Lin, M. H., Chao, M. W., Peng, S. J., Hsu, K. C., Eight Lin, T., Chen, M. C., Lai, M. J., Pan, S. L. & Liou, J. P., Oct 1 2019, In : Bioorganic Chemistry. 91, 103119.

Research output: Contribution to journal › Article

Growth Inhibitors
Amides
Prostatic Neoplasms
Cells
Lead compounds
3 Citations (Scopus)

Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation
1 Citation (Scopus)

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M. & Pan, S. L., May 29 2019, In : Clinical Epigenetics. 11, 1, 85.

Research output: Contribution to journal › Article

Open Access
Histone Deacetylase Inhibitors
Mitogen-Activated Protein Kinase Kinases
Pancreatic Neoplasms
Epidermal Growth Factor Receptor
Heterografts
1 Citation (Scopus)

MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells

Huang, F. I., Wu, Y. W., Sung, T. Y., Liou, J. P., Lin, M. H., Pan, S. L. & Yang, C. R., Jan 1 2019, In : Frontiers in Oncology. 9, APR, 249.

Research output: Contribution to journal › Article

Open Access
Histone Deacetylases
Multiple Myeloma
Neoplasms
Histone Deacetylase Inhibitors
Growth
7 Citations (Scopus)

1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC

Ojha, R., Huang, H. L., HuangFu, W. C., Wu, Y. W., Nepali, K., Lai, M. J., Su, C. J., Sung, T. Y., Chen, Y. L., Pan, S. L. & Liou, J. P., Apr 25 2018, In : European Journal of Medicinal Chemistry. 150, p. 667-677 11 p.

Research output: Contribution to journal › Article

Hydroxamic Acids
Histone Deacetylase Inhibitors
Antineoplastic Agents
Protein Isoforms
Cells